Bivalent gp41 inhibitors were 40–60-fold more potent than monomers. Binding potency was not significantly improved by dimerization. Potency was correlated to slower off-rates. Data could be explained by a bidentate binding model for the dimers. The kinetic dependence may be due to transience of the targeted intermediate.